Cachexia is a complex and extremely variable syndrome characterised by weight loss, anorexia, and negative nitrogen balance and is present in many cancer patients during the course of their disease.' 2 In children the cachexia is usually a result of the treatment rather than of the cancer itself. Moreover the protein requirements of children during therapy for malignancy are unknown, both at diagnosis when there is a large tumour burden and during treatment when there are the effects of anticancer drugs and infection. The aetiology of cachexia in children with cancer is multifactorial. Inadequate intake arising from anorexia, mucositis, or malabsorption due to the effects of anticancer drugs, and systemic metabolic factors arising from the effects of the malignancy, chemotherapy, or infection are likely to be contributory. However, since malignancies are typically very chemosensitive in children, very soon in treatment there is minimal or no tumour burden and therefore the major effect is of chemotherapy.
show that rates of synthesis and catabolism were higher in cancer patients than in controls. Thus whole body protein turnover is increased in children under treatment for cancer. Other indices of metabolism such as plasma amino acids and intermediary metabolites were also measured and showed that, although subjects were in isotopic steady state, there were significant metabolic changes during the course of the primed constant infusions used to measure protein turnover. Cachexia is a complex and extremely variable syndrome characterised by weight loss, anorexia, and negative nitrogen balance and is present in many cancer patients during the course of their disease.' 2 In children the cachexia is usually a result of the treatment rather than of the cancer itself. Moreover the protein requirements of children during therapy for malignancy are unknown, both at diagnosis when there is a large tumour burden and during treatment when there are the effects of anticancer drugs and infection. The aetiology of cachexia in children with cancer is multifactorial. Inadequate intake arising from anorexia, mucositis, or malabsorption due to the effects of anticancer drugs, and systemic metabolic factors arising from the effects of the malignancy, chemotherapy, or infection are likely to be contributory. However, since malignancies are typically very chemosensitive in children, very soon in treatment there is minimal or no tumour burden and therefore the major effect is of chemotherapy.
It has been known for some years that survival time is closely related to weight loss"'
and that the attendant loss of body protein is associated with increased rates of whole body protein turnover."' There have, however, been conflicting reports.'""5 The great majority of the literature is concerned with studies of adults with cancer and there are very few studies of children. An exception is two studies by Kien and Camitta,89 who, using the single dose "N-glycine technique, showed increased rates of whole body protein turnover in children with newly diagnosed leukaemia and lymphoma. Nutritional support to prevent loss of lean body mass is an integral part of treatment in cancer patients, which frequently takes the form of total parenteral nutrition. Improved nutritional status has a number of positive effects, it results in improved tolerance to chemotherapy in certain types of malignancy,"'2 improved immune competence,2" decreased incidence of opportunistic infections," and improved prognosis.2' 24 However, it is still uncertain how effective total parenteral nutrition is in reducing cachexia, and in particular what effect it has on protein metabolism. 25 Moreover, approximately 30% of children with cancer do not respond to this form of nutritional support.26 In order to obtain a better understanding of the effect that total parenteral nutrition has on protein metabolism in children it is necessary to make measures of whole body protein turnover.
Several techniques have been devised for the measurement of whole body protein turnover, based on the administration of stable isotopically labelled amino acids and the measurement of enrichment of either the parent amino acid or some metabolite. The most widely used and validated approach is to give [1-"C]leucine as a primed constant Daley, Pearson, Craft, Kernahan, Wyllie, Price, Brock, Hetherington, Halliday, Bartett (8) , neuroblastoma (7), acute lymphoblastic leukaemia (7), Ewing's sarcoma (2), non-Hodgkin's lymphoma (2), germ cell tumour (1), and astrocytoma (1). Their treatment was according to national or international protocols. They were studied at different stages of treatment: at diagnosis before treatment was started (7), during treatment (23) , and after the completion of treatment (6) . Seven of the children investigated during treatment had, or were recovering from, an infection at the time of study. Seven patients were catabolic and losing weight but only one was receiving any supplementary nutrition, by nasogastric feeding, at the time of study. Exclusion criteria for the study were as follows: (1) children receiving total parenteral nutrition, (2) children under the age of 2 years, (3) children without venous access necessary for clinical purposes. Chemotherapy was not given to any child at the time of study; however, three children were receiving dexamethasone. Informed consent was obtained from the parents of these children and the study was approved by the joint University/Newcastle Health Authority ethics committee. Clinical and anthropometric details of the patients studied are summarised in table 1 . were obtained from Promochem Limited. Isotopically labelled substrates were infused in a solution of normal saline that was shown to be sterile and pyrogen-free.
MEASUREMENTS OF WHOLE BODY PROTEIN TURNOVER
Rates of whole body protein turnover were assessed in 32 subjects by the [ring-
'H5]phenylalanine" and [1-`C]leucine`8 infusion methods. Whole body protein synthesis and catabolism was determined in 32 subjects using the phenylalanine model, and rates of protein synthesis were measured in 19 patients using the leucine model.
PROCEDURE
Patients were studied as outpatients or inpatients when admitted for clinical purposes to the children's cancer unit, Royal Victoria Infirmary. Patients were fasted overnight before the study and remained so for the duration of the investigation An intravenous cannula was inserted into a vein on the back of one hand for blood collection. Isotopes were infused through a central venous catheter, which was present as part of the normal management of these patients. In some studies a double lumen central venous catheter was used (patients [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . In this circumstance the infusion given through one lumen was halted for two minutes before sampling from the second lumen; a validation study comparing simultaneous central and peripheral sampling is described in Results which showed that this length of time was sufficient to avoid contamination of the sampling lumen with infusate and short enough to preclude compromising steady state conditions. After collection of baseline blood and expired air samples, priming bolus doses of over a 3 h period. Blood and expired air samples were collected at 90, 120, 135, 150, 165, and 180 minutes after the start of the infusion. Each blood sample was collected into heparinised tubes, immediately centrifuged at 4°C, and the plasma stored at -80°C until analysis. In the subjects in which leucine oxidation was determined, expired air total CO2 production rate was measured by open circuit indirect calorimetry using a ventilated hood system.29
Plasma and whole blood specimens were collected at the beginning and end of each infusion study for the measurement of amino acids and intermediary metabolites respectively.
ANALYSES
The enrichment of the transamination product
was measured rather than leucine because the latter is derived from the transamination of intracellular leucine and thus gives a better measure of the precursor enrichments for both leucine turnover and oxidation."0 Plasma 2-oxoisocaproic acid was extracted and converted to its quinoxalinol-trimethylsilyl derivative by the method of Ford et al." The "C enrichment was measured by electron-impact gas chromatography-mass spectrometry (Finnigan MAT 1020) using selected ion monitoring. The fragment ions of 2-oxoisocaproic acid measured by this process were m/z 232 and 233 for ["'C]/[`C] 2-oxoisocaproic acid. The "3C enrichment of expired carbon dioxide was determined by isotope ratio mass spectrometry (IRMS).
Plasma phenylalanine and tyrosine were extracted and converted to their t-butyldimethylsilyl derivatives as previously de- scribed.32 The deuterium enrichments of these derivatives were determined by electronimpact gas chromatography-mass spectrometry using selected ion monitoring. The fragment ions measured for both phenylalanine and tyrosine are 57 atomic mass units less than their molecular ions formed by the loss of a single butyl group. Therefore the fragment ions are m/z 336 and 341 for [2HJ2H5] phenylalanine and m/z 466 and 470 for [2HJ/H4]tyrosine.
Plasma amino acid concentrations were determined using a Beckmann 6300 amino acid analyser (System GoldTM). Blood intermediary metabolites and non-esterified fatty acids were measured enzymatically using a Cobas bio fast centrifugal analyser as previously described."
CALCULATIONS OF WHOLE BODY PROTEIN TURNOVER
Whole body protein turnover was calculated by applying steady state kinetics modified for stable isotope tracers. 28 In the steady state, amino acid flux for both phenylalanine and leucine (Q; pjmol/h/kg) was calculated by isotope dilution:
where I is the isotope infusion rate (nmol/h/kg), Ei is the enrichment of the labelled amino acid in the infusate (atom % excess, ape), and Ep is the enrichment of the labelled amino acid in plasma at isotopic steady state (ape). Peripheral sample enrichment (atoms % excess) Figure I It is a necessary condition for the measurement of whole body protein turnover by means of primed constant infusion that steady state conditions prevail with respect to isotopic enrichment and the concentrations of the tracers. We show this to be the case in our study population (fig 2, table 2 ). However, it is clear that during the course of infusions there are significant changes in glucose, NEFA, ketone bodies, and alanine as the overnight fast is continued for the duration of the infusions. These changes are the inevitable consequences of studies carried out under fasting conditions and would be observed in normal control individuals.
In studies reported by Thompson et al279 40 the kinetics of whole body protein turnover were measured in control groups of children using the same phenylalanine and leucine tracer techniques that have been employed in this study. As shown in table 7 
